Published Sept. 17, 2026
By Jonathan Gardner, Senior Biopharma Correspondent
In a high-stakes move to regain its competitive footing in the rapidly evolving landscape of cardiometabolic medicine, Novo has announced a landmark collaboration valued at up to $1.4 billion. The partnership, centered on the development of “macrocycle” technology, signals a shift in the pharmaceutical giant’s long-term R&D strategy: moving beyond traditional injectables to capture the “holy grail” of obesity treatment—the effective, daily oral pill.
This alliance represents more than just a capital investment; it is a fundamental technological pivot for a company currently navigating a massive internal restructuring. By leveraging the AI-driven drug discovery platform of Orbis Medicines, the company aims to overcome the biological barriers that have long prevented large, potent molecules from being absorbed by the human digestive tract.
The Core Partnership: Unlocking Oral Biologics
The collaboration focuses on the synthesis and optimization of macrocyclic peptides. While biologics like peptides and antibodies have revolutionized the treatment of diabetes and obesity, their clinical utility has historically been hampered by their delivery methods. Currently, patients must rely on subcutaneous injections or infusion therapies—regimens that, while effective, often face challenges regarding patient adherence and long-term convenience.
Macrocyclic peptides offer a unique middle ground. They possess the high potency and specificity of large-molecule biologics but are structured in a way that—if engineered correctly—can survive the harsh environment of the gastrointestinal tract and enter the bloodstream.
Orbis Medicines, a startup that emerged from stealth with $93 million in Series A funding in January 2025, has pioneered a proprietary platform known as “nCycles.” This platform integrates artificial intelligence to model the structural constraints of molecules, allowing researchers to design drugs that are orally bioavailable while retaining the ability to modulate difficult-to-reach targets, both inside and outside the cell. Under the terms of the agreement, the two companies will co-develop these candidates to address a pipeline of cardiometabolic conditions, including obesity and related metabolic syndrome disorders.
A Chronology of a Corporate Rebirth
The current trajectory of the company is inextricably linked to the intense pressure it has faced over the last 24 months. Once the undisputed leader in the GLP-1 revolution, the firm saw its market dominance challenged by the rapid ascent of Eli Lilly and other competitors.
- 2024 (The Year of Transition): Faced with increasing market share loss and supply chain bottlenecks, the company began a series of drastic operational changes. This included a comprehensive search for new leadership and a shift in R&D focus toward long-acting and oral formulations.
- Early 2025: The company underwent significant leadership changes, including the appointment of a new CEO, and initiated a widespread restructuring effort. This period was marked by difficult decisions, including corporate layoffs and a fundamental reorganization of its global board.
- Late 2025 – Early 2026: The push toward digitalization intensified. The company began integrating generative AI into its clinical trial design and molecular modeling pipelines.
- September 2026: In a symbolic move to match its internal transformation, the company announced a rebranding strategy, shortening its corporate identity to "Novo" in daily operations. This week’s $1.4 billion deal with Orbis serves as the latest pillar in this "New Novo" strategy, emphasizing a future defined by AI-enhanced chemistry.
Supporting Data: Why Macrocycles Matter
The pharmaceutical industry has been chasing the "pill-form" biologic for decades. The primary challenge is the "rule of five," a heuristic used to estimate the oral bioavailability of compounds. Most large molecules violate these rules because they are too heavy or lack the necessary chemical properties to pass through the intestinal wall.
Macrocycles break these rules by folding into compact, protected shapes that hide the chemical features that would otherwise be degraded by stomach acid.
Data from the broader sector supports this optimism:
- Market Success: Earlier this year, Merck & Co. achieved a significant milestone with the approval of Lipfendra (enlicitide), a cholesterol-lowering medication that proved the commercial viability of macrocyclic structures in a clinical setting.
- Venture Capital Interest: The sector has seen a surge in funding for companies like Unnatural Products and Dayra Therapeutics, both of which have recently inked their own partnerships with major pharmaceutical players, confirming a broader industry trend toward this chemical modality.
- Platform Efficiency: Orbis’s nCycles platform is reported to reduce the time from target identification to lead optimization by roughly 40% compared to traditional medicinal chemistry, a metric that likely heavily influenced the company’s decision to commit to such a high-value partnership.
Official Responses and Strategic Rationale
While the company has remained tight-lipped regarding the specific targets of the Orbis collaboration, internal statements suggest that the focus is on "next-generation cardiometabolic health."
"Our partnership with Orbis is a cornerstone of our efforts to modernize our drug discovery engine," a spokesperson noted in a press briefing following the announcement. "By combining our expertise in metabolic disease with Orbis’s nCycles platform, we are positioning ourselves to lead the next wave of oral therapies that prioritize patient quality of life and accessibility."
The company’s recent alignment with AI-first firms, most notably the high-profile alliance with Anthropic, underscores a shift in culture. The firm is no longer viewing itself solely as a manufacturing powerhouse, but as a data-driven biotechnology entity. This transition is critical, as analysts suggest the next decade of metabolic medicine will be won by the company that can best utilize "in silico" models to shorten the path to human trials.
Implications: The Future of Obesity Treatment
The implications of this $1.4 billion deal are profound for both the pharmaceutical industry and the millions of patients managing chronic weight-related conditions.
1. The End of the Injection Era?
If the collaborative efforts succeed, the standard of care for obesity could shift from a weekly injectable to a daily or even weekly oral pill. This would not only reduce the "injection burden" on patients but could also significantly lower the cost of manufacturing and distribution, potentially easing the supply shortages that have plagued the market for years.
2. A Competitive Resurgence
For the company, this is an existential pivot. By moving into the macrocycle space, they are attempting to leapfrog the current generation of GLP-1 therapies. If they can produce a molecule that is both orally stable and more potent than current offerings, they could effectively reset the competitive landscape, rendering the current lead held by competitors like Eli Lilly vulnerable to disruption.
3. The Role of AI in "Big Pharma"
This deal serves as a benchmark for how established, legacy pharmaceutical companies are integrating disruptive technologies. By partnering with agile startups like Orbis rather than attempting to build all R&D capabilities in-house, the company is adopting a "hub-and-spoke" model of innovation. This strategy allows them to mitigate the risks associated with unproven technologies while retaining the upside of being the primary commercialization partner.
4. Market Impact
The market reaction to the announcement has been one of cautious optimism. Investors have long called for a definitive strategy to differentiate the company’s portfolio. With this move, combined with the recent board restructuring and rebranding, the company is signaling that it is prepared to move past the "injection-only" era.
As we look toward the next five years, the success of this alliance will likely be measured by the speed at which these macrocycle candidates reach Phase 1 human trials. Should they prove successful, the pharmaceutical industry may look back at this week in September 2026 as the moment the "New Novo" truly began to take shape—a future where the power of biologics is delivered not by the needle, but by the convenience of a daily pill.
